Eli Lilly and Company: Carcinoma, Non-Small-Cell Lung trials

The registry lists 147 Carcinoma, Non-Small-Cell Lung studies with Eli Lilly and Company as lead sponsor. 6 are open to participants now and 87 have results posted.

Phase 1 41Phase 2 86Phase 3 25Phase 4 3No phase 5(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07928258Phase 1
• A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in IndiaNot yet recruitingNCT07822880Phase 4
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
• A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationActive, not recruitingNCT04280081Phase 2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Phase 3Results posted
• A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationTerminatedNCT04165031Phase 1/2Results posted
• A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerCompletedNCT04148937Phase 1Results posted
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
• Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerTerminatedNCT03382912Phase 2Results posted
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung CancerTerminatedNCT03382899Phase 2Results posted
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
• A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerCompletedNCT02789345Phase 1Results posted
• A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLCCompletedNCT02451930Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerCompletedNCT02450539Phase 2Results posted
• A Study of LY3023414 and Necitumumab in Squamous Lung CancerTerminatedNCT02443337Phase 2Results posted
• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results posted
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results posted
• A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02411591Phase 1Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
• A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCCompletedNCT02392507Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingNCT02152631Phase 3Results posted
• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerCompletedNCT02082210Phase 1/2Results posted
• A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)CompletedNCT02079636Phase 1Results posted
• A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their BodyTerminatedNCT02014116Phase 1Results posted
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT01900652Phase 2Results posted
• A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung CancerCompletedNCT01788566Phase 2Results posted
• A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung CancerCompletedNCT01769391Phase 2Results posted
• A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01763788Phase 1/2Results posted
• A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung CancerCompletedNCT01703091Phase 2Results posted
• A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-CisplatinCompletedNCT01606748Phase 2Results posted
• A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01473563Phase 2Results posted
• A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01469000Phase 2Results posted
• A Study in Non-Small Cell Lung CancerCompletedNCT01232452Phase 2Results posted
• A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based ChemotherapyCompletedNCT01168973Phase 3Results posted
• A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung CancerCompletedNCT01165021Phase 2Results posted
• A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01160744Phase 2Results posted
• A Study in Non Small Cell Lung CancerCompletedNCT01139775Phase 1/2Results posted
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsTerminatedNCT01115803Phase 1Results posted
• Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung CancerCompletedNCT01109524Phase 2Results posted
• Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung CancerCompletedNCT01107444Phase 2Results posted
• A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedNCT01059643Phase 2Results posted
• A Study in Non-squamous Non Small Cell Lung Cancer in Asian PatientsCompletedNCT01020786Phase 4Results posted
• A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung CancerCompletedNCT01017874Phase 3Results posted
• A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung CancerCompletedNCT01005680Phase 3Results posted
• A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell CancerCompletedNCT01004250Phase 2Results posted
• A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung CancerCompletedNCT01000480Phase 2Results posted
• A Study of Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT00988858Phase 2Results posted
• First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-CisplatinCompletedNCT00982111Phase 3Results posted
• First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-CisplatinCompletedNCT00981058Phase 3Results posted
• Study of Participants With Advanced Non-Small Cell Lung CancerCompletedNCT00948675Phase 3Results posted
• A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00918203Phase 2Results posted
• A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung CancerCompletedNCT00887549Phase 2Results posted
• A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy BeforeCompletedNCT00870870Phase 2Results posted
• A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung CancerCompletedNCT00867009Phase 2Results posted
• A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung CancerCompletedNCT00789373Phase 3Results posted
• A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung CancerCompletedNCT00762034Phase 3Results posted
• A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung CancerCompletedNCT00735696Phase 2Results posted
• Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung CancerCompletedNCT00686959Phase 3Results posted
• A Study for Patients With Non-Squamous Non-Small Cell Lung CancerCompletedNCT00609518Phase 2Results posted
• A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerCompletedNCT00606021Phase 2Results posted
• A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung CancerCompletedNCT00550173Phase 2Results posted
• Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With ChemotherapyCompletedNCT00533429Phase 2Results posted
• Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung CancerCompletedNCT00530621Phase 2Results posted
• Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung CancerCompletedNCT00529100Phase 1/2Results posted
• Chemotherapy in Treating Patients With Non-Small Cell Lung CancerCompletedNCT00520676Phase 3Results posted
• A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung CancerCompletedNCT00482014Phase 1/2Results posted
• A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung CancerCompletedNCT00452413Phase 1/2Results posted
• Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation TherapyCompletedNCT00415363Phase 2Results posted
• Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-SmokersCompletedNCT00409006Phase 2Results posted
• Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00402051Phase 2Results posted
• Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00391274Phase 3Results posted
• Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung CancerTerminatedNCT00383331Phase 2Results posted
• Chemotherapy for Patients With Non-Small Cell Lung CancerCompletedNCT00380718Phase 4Results posted
• Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00370292Phase 2Results posted
• Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung CancerCompletedNCT00363766Phase 2Results posted
• Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly PatientsCompletedNCT00350792Phase 2Results posted
• A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLCCompletedNCT00343291Phase 2Results posted
• Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or AbdomenCompletedNCT00316225Phase 2Results posted
• First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00308750Phase 2Results posted
• Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung CancerCompletedNCT00269152Phase 2Results posted
• Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung CancerTerminatedNCT00259285Phase 2Results posted
• Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung CancerCompletedNCT00192036Phase 2Results posted
• Molecular Profiling in Lung Cancer PatientsCompletedNCT00191308Phase 2Results posted
• To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)CompletedNCT00191191Phase 2Results posted
• Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)CompletedNCT00191139Phase 2Results posted
• Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT00112294Phase 3Results posted
• Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00102804Phase 3Results posted
• Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung CancerCompletedNCT00095199Phase 3Results posted
• A Study of LY4175408 in Participants With Advanced CancerActive, not recruitingNCT07046923Phase 1
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsActive, not recruitingNCT06586515Phase 1
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06561685Phase 1
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentCompletedNCT05241834Phase 1
• Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET InhibitorNo longer availableNCT05225259